Stack Components.
FDA Approved
Appetite Controller
FDA-approved GLP-1 receptor agonist with the most extensive clinical evidence for weight management. 14.9% mean weight loss in STEP 1.
In this stack: The primary caloric restriction driver. Semaglutide acts on hypothalamic appetite centers and delays gastric emptying, producing a sustained reduction in food intake without the willpower depletion of conscious restriction. This creates the caloric deficit that the other compounds leverage for fat mobilization and oxidation.
FDA Approved
Visceral Fat Targeting
FDA-approved GHRH analog that specifically reduces visceral adipose tissue through pulsatile GH release.
In this stack: Targets the most metabolically dangerous fat depot. Visceral fat is disproportionately associated with insulin resistance, cardiovascular disease, and systemic inflammation. Tesamorelin selectively reduces trunk fat by 15-18% while preserving subcutaneous fat and lean mass, addressing a compartment that general caloric restriction reduces slowly.
Research
Expenditure Enhancer
NNMT inhibitor that increases cellular energy expenditure by restoring NAD+ availability and activating AMPK/sirtuin pathways.
In this stack: Increases the expenditure side of the energy balance equation. While semaglutide reduces intake, 5-Amino-1MQ boosts cellular energy expenditure through NNMT inhibition. This dual approach accelerates the net caloric deficit beyond what either mechanism achieves alone.